These recommendations advocated for utilizing multifaceted cardiac surveillance tests, such as echocardiogram and B-type natriuretic peptide (BNP), for early detection of cardiac dysfunction among breast cancer patients who received anthracycline therapy [27–30]. The gene discussed is NPPB; the disease is breast carcinoma.